Show Summary Details
Page of

Prolotherapy in the UK 

Prolotherapy in the UK
Chapter:
Prolotherapy in the UK
Author(s):

Simon Petrides

and Simon Petrides

DOI:
10.1093/med/9780199674107.003.0055
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 26 November 2020

Prolotherapy has become an accepted intervention in the UK for a variety of musculoskeletal complaints including back pain, despite its controversial 80-year history and failure, so far, to enter mainstream practice. Prolotherapy injections are used in the UK, USA, Australia, and New Zealand for a broad range of subacute and chronic recalcitrant musculoskeletal disorders. Originally, the injections were called ‘sclerosant therapy’ on the assumption of scar formation, but the term ‘prolotherapy’ is now widely used since it implies a proliferation of normal connective tissue which more closely represents the regeneration effect of the injections. Other terms used are ‘fibro-proliferative therapy’ or ‘regenerative injection therapy’. Other forms of prolotherapy include autologous blood injection, platelet-rich plasma injection, autologous conditioned plasma injection, dry needling, and stem cell therapy.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.